<DOC>
	<DOCNO>NCT00494338</DOCNO>
	<brief_summary>A multi-center control , non-comparative open Phase II trial docetaxel celecoxib patient metastatic androgen independent prostate cancer efficacy measure PSA response define 50 % reduction PSA maintain two consecutive evaluation least 4 week apart .</brief_summary>
	<brief_title>Phase II Trial Docetaxel Celecoxib Patients With Androgen Independent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients histologically confirm MAIPC Documented progressive disease bone , soft tissue PSA despite castrate level testosterone If LHRH agonist use previously must keep Previous antiandrogen hold least 4 week flutamida cyproterone 6 week bycalumida Previous DES hold least 4 week partcipating trial Chemotherapy naive patient No prior radioisotope Less 25 % bone marrow irradiate prior palliative radiotherapy KPS &gt; 70 % Adequate hematologic , hepatic renal function Patients serious medical illness History significant active cardiac disease History gastrointestinal ulceration , bleed perforation History myocardial infarctin within past 12 month Allergy sulfonamide celecoxib history urticaria NSAID The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Metastatic Androgen Independent Prostate Cancer ( MAIPC )</keyword>
</DOC>